Evidence map›Paper›PMID 26721668›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

Statistical Methods for Estimating the Cumulative Risk of Screening Mammography Outcomes.

Rebecca A Hubbard, Theodora M Ripping, Jessica Chubak, Mireille J M Broeders, Diana L Miglioretti

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Performance of Statistical and Machine Learning Risk Prediction Models for Advanced Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rebecca A HubbardDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. rhubb@mail.med.upenn.edu.
Theodora M RippingRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Jessica ChubakGroup Health Research Institute, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
Mireille J M BroedersRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Dutch Reference Centre for Screening, Nijmegen, the Netherlands.
Diana L MigliorettiGroup Health Research Institute, Seattle, Washington. Department of Public Health Sciences, University of California, Davis, California.

Funding

Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Vermont Screening Process Documentation UnitU54CA163303 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L · 2011 to 2017
$6.4M
Statistical Methods for Estimation of Benefits & Harms of Repeat Cancer ScreeningR03CA182986 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HUBBARD, REBECCA · 2014 to 2015
$160k
NCI NIH HHS HHSN261201100031CNCI NIH HHS P01 CA154292NCI NIH HHS P01CA154292NCI NIH HHS R03 CA182986NCI NIH HHS R03CA182986NCI NIH HHS U54 CA163303NCI NIH HHS U54CA163303
6 · The paper itself

Abstract

backgroundThis study illustrates alternative statistical methods for estimating cumulative risk of screening mammography outcomes in longitudinal studies.

methodsData from the US Breast Cancer Surveillance Consortium (BCSC) and the Nijmegen Breast Cancer Screening Program in the Netherlands were used to compare four statistical approaches to estimating cumulative risk. We estimated cumulative risk of false-positive recall and screen-detected cancer after 10 screening rounds using data from 242,835 women ages 40 to 74 years screened at the BCSC facilities in 1993-2012 and from 17,297 women ages 50 to 74 years screened in Nijmegen in 1990-2012.

resultsIn the BCSC cohort, a censoring bias model estimated bounds of 53.8% to 59.3% for false-positive recall and 2.4% to 7.6% for screen-detected cancer, assuming 10% increased or decreased risk among women screened for one additional round. In the Nijmegen cohort, false-positive recall appeared to be associated with subsequent discontinuation of screening leading to overestimation of risk of a false-positive recall based on adjusted discrete-time survival models. Bounds estimated by the censoring bias model were 11.0% to 19.9% for false-positive recall and 4.2% to 9.7% for screen-detected cancer.

conclusionChoice of statistical methodology can substantially affect cumulative risk estimates. The censoring bias model is appropriate under a variety of censoring mechanisms and provides bounds for cumulative risk estimates under varying degrees of dependent censoring. IMPACT: This article illustrates statistical methods for estimating cumulative risks of cancer screening outcomes, which will be increasingly important as screening test recommendations proliferate.

Indexed as

AgedBreast NeoplasmsEarly Detection of CancerFemaleHumansMammographyMiddle AgedTreatment Outcome

Identifiers

PMID26721668
PMCPMC4779749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.